Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27
Vor Biopharma, Inc.
Vor Biopharma, Inc. VOR | 0.00 |
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:
VOR) with a Neutral and raises the price target from $18 to $27.
